Showing results (401-410 of 418) with videos related to
Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|March 30, 2020
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance statusFrancesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, et al.Journal for Immunotherapy of Cancer|May 21, 2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.Trials|December 19, 2025
Treatment guided by cerebral oximetry in mechanically ventilated newborns: a statistical analysis plan for step one of the SafeBoosC-IIIv randomised clinical trialJohanne Juul Petersen, Caroline Barkholt Kamp, Markus Harboe Olsen, et al.Trials|March 18, 2026
Treatment guided by cerebral oximetry in newborns receiving invasive mechanical ventilation: study protocol for step one of the SafeBoosC-IIIv randomised clinical trialCaroline Barkholt Kamp, Johanne Juul Petersen, Mathias Lühr Hansen, et al.Immunotherapy|October 18, 2018
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa studyMelissa Bersanelli, Diana Giannarelli, Paola Castrignanò, et al.Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.Cancer Immunology, Immunotherapy : CII|August 31, 2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuationMarco Russano, Alessio Cortellini, Raffaele Giusti, et al.Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.Pageof 42